Risk of malignancy in psoriatic patients: Our clinical experience

Magnano, Michela; Loi, Camilla; Sechi, Andrea; Sgubbi, Paola; Raone, Beatrice; Patrizi, Annalisa; Bardazzi, Federico

doi:10.1111/dth.12476

Cited by 6 publications

(6 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These data are in line with what we observed while considering 356 continuous patients referring to our clinic 38 . Only nine out of the total developed a neoplasia during a mean follow‐up of 28.6 months and in particular six were on anti‐TNF‐α and three in traditional systemic therapies 38 . Thus, according to our data, the risk of tumor in biotechnological therapy is quite low 38 …”

Section: Surgical Proceduressupporting

confidence: 90%

“…With regard to malignancies, as almost all authors agree in the safety of biotechnological therapies, 10,11,16,38 there is no joint line about their suspension in case of new diagnosis 39‐41 . Thus, any case should be evaluated by clinicians.…”

Section: Discussionmentioning

confidence: 99%

“…To conclude, biotechnological therapies seem to be safe 10,11,38 and, in selected circumstances, their use should be considered even in the case of previous malignancies 16 …”

Section: Surgical Proceduresmentioning

confidence: 99%

See 2 more Smart Citations

The unforeseen during biotechnological therapy for moderate‐to‐severe psoriasis: How to manage pregnancy and breastfeeding, infections from Mycobacterium tuberculosis , hepatitis B virus, hepatitis C virus, and HIV , surgery, vaccinations, diagnosis of malignancy, and dose tapering

Sacchelli

Magnano

Loi

et al. 2020

Dermatologic Therapy

Self Cite

View full text Add to dashboard Cite

The use of biotechnological therapies for moderate‐to‐severe psoriasis is ever‐expanding and it is becoming increasingly more frequent to encounter different unforeseen events during their use, such as fertile patients becoming pregnant and breastfeeding, development of infections due to personal habits like tuberculosis, hepatitis B virus, hepatitis C virus, or HIV, scheduling of surgical procedures, need of vaccinations, development of malignancy, and evaluation of dose tapering. As any clinician may experience at least one of these unexpected events, it should be good practice to know how to manage them. Thus, a practical analysis has been proposed in this study.

show abstract

Section: Surgical Proceduressupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The unforeseen during biotechnological therapy for moderate‐to‐severe psoriasis: How to manage pregnancy and breastfeeding, infections from Mycobacterium tuberculosis , hepatitis B virus, hepatitis C virus, and HIV , surgery, vaccinations, diagnosis of malignancy, and dose tapering

Sacchelli

Magnano

Loi

et al. 2020

Dermatologic Therapy

Self Cite

View full text Add to dashboard Cite

show abstract

“…We read with great interest the recent article by Magnano et al (2017) which showed that the risk of malignancy seemed not to be increased in their cohort of psoriatic patients treated with biologic drugs. Since long term effects of biologic drugs, especially on malignancy risk, is still a major matter of debate, we conducted a 12-year retrospective study (January 2005 Magnano et al (2017), showing that biologic treatment seemed not to increase malignancy risk in psoriasis patients. The frequency of malignancy was comparable between subjects treated with biologics or conventional drugs.…”

Section: Dear Editormentioning

confidence: 99%

“…Magnano et al (2017), showing that biologic treatment seemed not to increase malignancy risk in psoriasis patients. The frequency of malignancy was comparable between subjects treated with biologics or conventional drugs.…”

mentioning

confidence: 99%

Systemic treatment for psoriasis and malignancies: A real risk?

Napolitano

Megna

Patrì

et al. 2017

Dermatologic Therapy

View full text Add to dashboard Cite

Prevalence, Incidence, and Risk of Cancer in Patients With Psoriasis and Psoriatic Arthritis

et al. 2020

View full text Add to dashboard Cite

IMPORTANCEThe association between psoriasis and risk of cancer remains debatable.OBJECTIVE To evaluate the association and risk of cancer in patients with psoriasis or psoriatic arthritis, including risk of specific cancer subtypes.DATA SOURCES Two databases (PubMed and Embase) were screened from inception to January 1, 2019, using the search string psoriasis or psoriatic and neoplasms or malignancy or cancer. The search was filtered to only include human participants and publications in English.STUDY SELECTION Observational cohort studies with a population of patients with psoriasis or psoriatic arthritis were included. Studies had to be original and report the incidence or prevalence of cancer within this population. Studies evaluating pediatric populations and cancer types not included in the protocol were excluded. DATA EXTRACTION AND SYNTHESISThis study was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. The search string, objectives, and study protocol methods were defined before the study was initiated. A total of 365 studies were included for full-text assessment. Owing to the heterogeneity of the included studies, a random-effects model was used.MAIN OUTCOMES AND MEASURES Main outcome was cancer (overall and specific subtypes) and measures were prevalence, incidence, and risk estimate for cancer in patients with psoriasis or psoriatic arthritis. RESULTSOf the 365 studies assessed, 112 were included in the analysis (N = 2 053 932 patients). The overall prevalence of cancer in patients with psoriasis was 4.78% (95% CI, 4.02%-5.59%), with an incidence rate of 11.75 per 1000 person-years (95% CI, 8.66-15.31) and a risk ratio (RR) of 1.21 (95% CI, 1.11-1.33). There was an increased risk of several cancers, including keratinocyte cancer (RR, 2.28; 95% CI, 1.73-3.01), lymphomas (RR, 1.56; 95% CI, 1.37-1.78), lung cancer (RR, 1.26; 95% CI, 1.13-1.40), and bladder cancer (RR, 1.12; 95% CI, 1. 04-1.19). No increased risk of cancer for patients with psoriasis treated with biologic agents was found (RR, 0.97; 95% CI, 0.85-1.10). Psoriatic arthritis was not associated with increased risk of cancer overall (RR, 1.02; 95% CI, 0.97-1.08).CONCLUSIONS AND RELEVANCE Patients with psoriasis appear to have a slightly increased risk of cancer, particularly keratinocyte cancer and lymphomas. Data on treatment with biologic agents did not show an increased risk of cancer. Data on cancer in patients with psoriatic arthritis remain scarce, and further research is warranted in this area.

show abstract

Risk of malignancy in psoriatic patients: Our clinical experience

Cited by 6 publications

References 5 publications

The unforeseen during biotechnological therapy for moderate‐to‐severe psoriasis: How to manage pregnancy and breastfeeding, infections from Mycobacterium tuberculosis , hepatitis B virus, hepatitis C virus, and HIV , surgery, vaccinations, diagnosis of malignancy, and dose tapering

The unforeseen during biotechnological therapy for moderate‐to‐severe psoriasis: How to manage pregnancy and breastfeeding, infections from Mycobacterium tuberculosis , hepatitis B virus, hepatitis C virus, and HIV , surgery, vaccinations, diagnosis of malignancy, and dose tapering

Systemic treatment for psoriasis and malignancies: A real risk?

Prevalence, Incidence, and Risk of Cancer in Patients With Psoriasis and Psoriatic Arthritis

Contact Info

Product

Resources

About